文献速递临床试验与 GCP流行病学与生物统计

罗库溴铵与琥珀胆碱对院外快速序贯插管成功率的影响:随机临床试验

Effect of Rocuronium vs Succinylcholine on Endotracheal Intubation Success Rate Among Patients Undergoing Out-of-Hospital Rapid Sequence Intubation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项多中心、单盲、非劣效性随机临床试验纳入1248例需院外气管插管的成人患者,比较罗库溴铵(1.2 mg/kg)与琥珀胆碱(1 mg/kg)的首次插管成功率。主要分析显示罗库溴铵组首次插管成功率为74.6%,琥珀胆碱组为79.4%,组间差异-4.8%(单侧97.5%CI -9%至∞),未达到7%的非劣效界值。

要点

  • 罗库溴铵1.2 mg/kg在院外急诊插管中未证明非劣效于琥珀胆碱1 mg/kg。
  • 首次插管成功率罗库溴铵组74.6%,琥珀胆碱组79.4%,绝对差异-4.8%。
  • 两组常见插管相关不良事件为低氧血症和低血压。

核心结论

  • 在院外急诊气管插管患者中,与琥珀胆碱相比,罗库溴铵未能证明在首次插管成功率方面具有非劣效性。

研究设计与样本

  • 多中心、单盲、非劣效性随机临床试验,于2014年1月至2016年8月在法国17个院外急诊医疗单位纳入1248例需气管插管的成人患者。
  • 患者随机接受罗库溴铵1.2 mg/kg(n=624)或琥珀胆碱1 mg/kg(n=624)辅助气管插管,主要分析为符合方案集分析。
  • 主要结局为首次插管成功率,非劣效界值设为7%。

主要发现

  • 符合方案集分析中,罗库溴铵组610例中455例(74.6%)首次插管成功,琥珀胆碱组616例中489例(79.4%)成功。
  • 组间差异为-4.8%(单侧97.5%CI -9%至∞),未达到非劣效性标准。
  • 罗库溴铵组常见插管相关不良事件为低氧血症55/610(9.0%)和低血压39/610(6.4%);琥珀胆碱组为低氧血症61/616(9.9%)和低血压62/616(10.1%)。

临床怎么用

  • 在院外急诊快速序贯插管中,选择罗库溴铵替代琥珀胆碱时需考虑其首次插管成功率可能较低,应结合临床情况和药物可及性个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Rocuronium and succinylcholine are often used for rapid sequence intubation, although the comparative efficacy of these paralytic agents for achieving successful intubation in an emergency setting has not been evaluated in clinical trials. Succinylcholine use has been associated with several adverse events not reported with rocuronium. OBJECTIVE: To assess the noninferiority of rocuronium vs succinylcholine for tracheal intubation in out-of-hospital emergency situations. DESIGN, SETTING AND PARTICIPANTS: Multicenter, single-blind, noninferiority randomized clinical trial comparing rocuronium (1.2 mg/kg) with succinylcholine (1 mg/kg) for rapid sequence intubation in 1248 adult patients needing out-of-hospital tracheal intubation. Enrollment occurred from January 2014 to August 2016 in 17 French out-of-hospital emergency medical units. The date of final follow-up was August 31, 2016. INTERVENTIONS: Patients were randomly assigned to undergo tracheal intubation facilitated by rocuronium (n = 624) or succinylcholine (n = 624). MAIN OUTCOMES AND MEASURES: The primary outcome was the intubation success rate on first attempt. A noninferiority margin of 7% was chosen. A per-protocol analysis was prespecified as the primary analysis. RESULTS: Among 1248 patients who were randomized (mean age, 56 years; 501 [40.1%] women), 1230 (98.6%) completed the trial and 1226 (98.2%) were included in the per-protocol analysis. The number of patients with successful first-attempt intubation was 455 of 610 (74.6%) in the rocuronium group vs 489 of 616 (79.4%) in the succinylcholine group, with a between-group difference of -4.8% (1-sided 97.5% CI, -9% to ∞), which did not meet criteria for noninferiority. The most common intubation-related adverse events were hypoxemia (55 of 610 patients [9.0%]) and hypotension (39 of 610 patients [6.4%]) in the rocuronium group and hypoxemia (61 of 616 [9.9%]) and hypotension (62 of 616 patients [10.1%]) in the succinylcholine group. CONCLUSIONS AND RELEVANCE: Among patients undergoing endotracheal intubation in an out-of-hospital emergency setting, rocuronium, compared with succinylcholine, failed to demonstrate noninferiority with regard to first-attempt intubation success rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02000674.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Guihard B, Chollet-Xémard C, Lakhnati P, et al. Effect of Rocuronium vs Succinylcholine on Endotracheal Intubation Success Rate Among Patients Undergoing Out-of-Hospital Rapid Sequence Intubation: A Randomized Clinical Trial. JAMA. 2019. PMID: 31846014. doi:10.1001/jama.2019.18254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。